Previous 10 | Next 10 |
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2024 financial results and operational highlights in a confer...
2024-04-30 13:25:04 ET Summary CRISPR/Cas9 technology allows for precise editing of DNA, potentially treating human diseases by replacing entire genes. CRISPR Therapeutics has developed the first FDA-approved ex vivo CRISPR/Cas9 therapy, Casgevy, for sickle cell disease and transf...
Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free through the latest follow-up Intellia to host investor webcast on Monday, June 3, at 8 a.m. ET CAMBRIDGE, Mass., April 29, ...
2024-04-19 03:54:17 ET Summary ARK Invest's 13F portfolio value decreased by 15% this quarter, with the number of holdings increasing from 223 to 230. The top three holdings in the portfolio are Coinbase Global, Tesla, and Block, making up around 20% of the assets. ARK Invest ...
2024-04-14 05:55:00 ET The bull market is roaring higher, and many growth stocks have led the gains -- but this doesn't mean your opportunity to buy growth stocks for a good price is over. Plenty of players with great long-term prospects haven't yet benefited from this favorable market envi...
2024-04-12 04:50:00 ET Cathie Wood is known for her investments in disruptive technologies that are changing or have the potential to change the way things are done. She's built a solid reputation as a stock picker, aiming to beat the market over the long term by buying innovative companies...
2024-04-02 11:36:00 ET More on CRISPR Therapeutics Crispr Therapeutics: I'm Not Betting Against Gene Editing This Time (Upgrade) Crispr Therapeutics: Cautiously Optimistic CRISPR Therapeutics AG (CRSP) Presents at Citi 2024 Virtual Oncology Leadership Summit Conferen...
2024-03-28 05:55:00 ET Cathie Wood's latest stocks shopping spree included several healthcare innovators -- and she picked them up for a bargain. Wood isn't intimidated by shares that have wallowed in the doldrums because she favors long-term investing. The idea is to buy promising companie...
2024-03-22 12:40:30 ET Intellia Therapeutics ( NASDAQ: NTLA ) is opting out of an agreement with Regeneron Pharmaceuticals ( NASDAQ: REGN ) to co-develop a factor IX gene editing therapy for hemophilia A and B, the biotechnology firm disclosed in a filing on Friday.... ...
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient dosed in the global pivotal, Phase 3 MAGNITUDE trial of ...
News, Short Squeeze, Breakout and More Instantly...
Intellia Therapeutics Inc. Company Name:
NTLA Stock Symbol:
NASDAQ Market:
Intellia Therapeutics Inc. Website:
2024-07-13 10:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...